Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.795 USD | +0.65% | +8.90% | -83.79% |
03-15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
03-14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 15.19 | 6.884 | 4.842 | 2.912 | - | - |
Enterprise Value (EV) 1 | 15.19 | 6.884 | 4.842 | 2.912 | 2.912 | 2.912 |
P/E ratio | -0.34 x | -0.36 x | -0.51 x | -0.34 x | -0.58 x | -5.64 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 0.19 x | 0.1 x |
EV / Revenue | - | - | - | - | 0.19 x | 0.1 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -3,281,594 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 55.7 | 404 | 987 | 3,686 | - | - |
Reference price 2 | 273.0 | 17.04 | 4.905 | 0.7899 | 0.7899 | 0.7899 |
Announcement Date | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 15.58 | 30.54 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -6.063 | -9.258 | -9.378 | -9.81 | -10.66 | -14.13 |
Operating Margin | - | - | - | - | - | -68.46% | -46.25% |
Earnings before Tax (EBT) 1 | - | -21.46 | -9.382 | -8.687 | -10 | -10.38 | -1.828 |
Net income 1 | -2.095 | -21.46 | -9.447 | -8.687 | -10 | -10.38 | -1.828 |
Net margin | - | - | - | - | - | -66.62% | -5.99% |
EPS 2 | -315.0 | -813.0 | -46.80 | -9.640 | -2.310 | -1.370 | -0.1400 |
Free Cash Flow | - | -4.63 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 16/06/21 | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT | -1.303 | -2.981 | -2.176 | -2.668 | -2.328 | -2.086 | -2.776 | -2.26 | -2.125 | -2.218 | - | -2.515 | -2.557 | -2.601 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | -11.82 | -1.683 | -2.668 | -3.03 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | - | -2.515 | -2.557 | -2.601 |
Net income | -1.404 | -11.82 | -1.683 | -2.668 | -3.095 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | - | -2.515 | -2.557 | -2.601 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | -211.5 | 634.5 | -30.00 | -38.88 | -11.28 | -4.955 | -4.080 | -2.130 | -1.950 | -2.080 | - | -0.5000 | -0.5000 | -0.5100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 20/12/21 | 14/04/22 | 23/05/22 | 18/08/22 | 10/11/22 | 09/03/23 | 09/05/23 | 03/08/23 | 09/11/23 | 13/03/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -4.63 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 16/06/21 | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.79% | 2.91M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- QNRX Stock
- Financials Quoin Pharmaceuticals, Ltd.